These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 9345379

  • 1. Comparative evaluations of neuroperformance and clinical outcome assessments in chronic progressive multiple sclerosis: I. Reliability, validity and sensitivity to disease progression. Multiple Sclerosis Study Group.
    Syndulko K, Ke D, Ellison GW, Baumhefner RW, Myers LW, Tourtellotte WW.
    Mult Scler; 1996 Oct; 2(3):142-56. PubMed ID: 9345379
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group.
    Ann Neurol; 1990 Jun; 27(6):591-605. PubMed ID: 2193613
    [Abstract] [Full Text] [Related]

  • 4. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group.
    Schwartz CE, Vollmer T, Lee H.
    Neurology; 1999 Jan 01; 52(1):63-70. PubMed ID: 9921850
    [Abstract] [Full Text] [Related]

  • 5. Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity.
    Goodkin DE, Rudick RA, VanderBrug Medendorp S, Greene T, Schwetz KM, Fischer J, Daughtry MM, Ross J, Van Dyke C.
    Online J Curr Clin Trials; 1992 Sep 25; Doc No 19():[7723 words; 89 paragraphs]. PubMed ID: 1343611
    [Abstract] [Full Text] [Related]

  • 6. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH.
    Mult Scler; 1995 Jun 25; 1(2):118-35. PubMed ID: 9345462
    [Abstract] [Full Text] [Related]

  • 7. Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules.
    Rao SM, Galioto R, Sokolowski M, McGinley M, Freiburger J, Weber M, Dey T, Mourany L, Schindler D, Reece C, Miller DM, Bethoux F, Bermel RA, Williams JR, Levitt N, Phillips GA, Rhodes JK, Alberts J, Rudick RA.
    Eur J Neurol; 2020 May 25; 27(5):878-886. PubMed ID: 32009276
    [Abstract] [Full Text] [Related]

  • 8. Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial.
    Koziol JA, Lucero A, Sipe JC, Romine JS, Beutler E.
    Can J Neurol Sci; 1999 Nov 25; 26(4):283-9. PubMed ID: 10563213
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical outcome measures for research in multiple sclerosis.
    Balcer LJ.
    J Neuroophthalmol; 2001 Dec 25; 21(4):296-301. PubMed ID: 11756863
    [Abstract] [Full Text] [Related]

  • 11. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
    Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, Mass M, Balcer LJ.
    Neurology; 2005 Mar 22; 64(6):992-5. PubMed ID: 15781814
    [Abstract] [Full Text] [Related]

  • 12. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 22; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 13. Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study Group.
    Zhao GJ, Li DK, Wolinsky JS, Koopmans RA, Mietlowski W, Redekop WK, Riddehough A, Cover K, Paty DW.
    J Neuroimaging; 1997 Jan 22; 7(1):1-7. PubMed ID: 9038425
    [Abstract] [Full Text] [Related]

  • 14. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.
    Warren KG, Catz I, Ferenczi LZ, Krantz MJ.
    Eur J Neurol; 2006 Aug 22; 13(8):887-95. PubMed ID: 16879301
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.